Latest stories on TYRA
Tyra Biosciences, Inc. (TYRA) files 8-K
SEC 8-K50 · neutralgeneral
Cantor Fitzgerald reiterates Tyra Biosciences stock rating
Investing.com Analyst Ratings50 · neutralanalyst
Why is Tyra Biosciences stock surging today?
Investing.com Markets50 · neutralgeneral
Tyra Biosciences prices $400 million equity offering to fund dabogratinib development and other programs
Seeking Alpha24 · bearishgeneral
Tyra Biosciences prices $400M underwritten offering of common stock and warrants
The Fly26 · bearishgeneral
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PR Newswire24 · bearishgeneral
Tyra Biosciences files automatic mixed securities shelf
The Fly44 · neutralgeneral
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow
Seeking Alpha55 · neutralproduct/pr
Tyra Biosciences price target lowered to $30 from $45 at H.C. Wainwright
The Fly34 · bearishanalyst
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines
Seeking Alpha28 · bearishearnings
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
Investors.com38 · neutralproduct/pr
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barron's28 · bearishproduct/pr
Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial
MarketWatch34 · bearishproduct/pr
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
InvestorsHub32 · bearishproduct/pr
Why is Tyra Biosciences stock plunging today?
Investing.com Markets32 · bearishgeneral
Tyra Biosciences stock tumbles 30% on phase 2 trial results
Investing.com Markets28 · bearishearnings
Tyra drops after mid-stage trial data for lead asset in bladder cancer
Seeking Alpha32 · bearishproduct/pr
Tyra Bioscience Reports Promising Phase 2 Dabogratinib Data
TipRanks67 · bullishproduct/pr
Tyra Biosciences, Inc. (TYRA) files 8-K
SEC 8-K50 · neutralgeneral
Tyra Biosciences reports results from Phase 2 study of SURF302
The Fly63 · neutralproduct/pr
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
PR Newswire56 · neutralgeneral
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts
Seeking Alpha46 · neutralanalyst
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
Stocktwits News67 · bullishproduct/pr